NVAX Stock: Price, Earnings History and SEC Filings
Novavax, Inc. (NVAX) last traded at $10.08, down 3.72% on the latest session and down 6.8% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.32 against an analyst estimate of $-0.36, a beat of 11.1%.
$10.08 -3.72%
1 month-6.75%
52-week high$13.39
52-week low$6.20
Volume4.06M
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
NVAX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $-0.32 | $-0.36 | +11.11% |
| Mar 2026 | May 6, 2026 | $-0.06 | $-0.25 | +76.00% |
| Dec 2025 | Feb 26, 2026 | $0.11 | $-0.66 | +116.67% |
| Sep 2025 | Nov 6, 2025 | $-0.62 | $-1.08 | +42.59% |
NVAX beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for NVAX
SEC filing data is not available right now. You can search for NVAX on SEC EDGAR.
NVAX news
- Novavax stock: Sanofi trial triggers $125 million milestoneOct 30, 2026 · ad-hoc-news.de
- Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in EuropeOct 29, 2026 · finance.yahoo.com
- Novavax (NVAX) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseOct 29, 2026 · finance.yahoo.com
- Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026Oct 29, 2026 · finance.yahoo.com
- Novavax Gains $125 Mln Payment As Sanofi Begins Phase 3 Combination Vaccine Trial; Stock UpOct 29, 2026 · rttnews.com
- Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge HigherOct 28, 2026 · 247wallst.com
- Novavax (NVAX) Stock Falls Amid Market Uptick: What Investors Need to KnowOct 26, 2026 · finance.yahoo.com
- What Novavax Doubters OverlookedOct 24, 2026 · finance.yahoo.com
About Novavax, Inc.
Novavax, Inc. (NVAX) is a US-listed public company on Nasdaq.